Posted by Michael Wonder on 09 Nov 2021
BerGenBio receives FDA fast track designation for bemcentinib in STK11 mutated advanced/metastatic non-small-cell lung cancer
9 November 2021 - BerGenBio today announces that the U.S. FDA has granted fast track designation for bemcentinib in combination with an anti-PD-(L)1 agent as treatment for patients with STK11 altered advanced/metastatic non-small-cell lung cancer patients without actionable mutations.
The company’s proprietary lead candidate, bemcentinib, is a potentially first in class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in cancer and COVID-19.
